Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Results of TRITON-TIMI 38 trials

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 1, 2009, Pages 17-23

  Mariani, Matteo ^a   Mariani, Giuseppe ^a   de Servi, Stefano ^a  

^a Ospedale Civile di Legnano   (Italy)

Author keywords

Acute coronary syndromes; Antiplatelet therapy; TRITON TIMI 38

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; THROMBIN INHIBITOR; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PURINERGIC P2 RECEPTOR; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COLON TUMOR; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; NEUTROPENIA; NONST ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RISK REDUCTION; ST ELEVATION MYOCARDIAL INFARCTION; ST SEGMENT ELEVATION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS; AGED; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PURINERGIC P2; THIOPHENES; TICLOPIDINE;

EID: 60549095821     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.1.17     Document Type: Article

References (22)

1. Anderson JL, Adams CD, Amman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J. Am. Coll. Cardiol. 50, e1-e157 (2007).
2. Yusuf S, Zhao F, Mehta SR et al.; The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-7502 (2001).
3. Steinhubl SR, Berger PB, Mann JT III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411-2420 (2002).
4. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am. J. Cardiol. 91, 1123-1125 (2003).
5. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45, 246-251 (2005).
6. Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 153 (66), e9-e16 (2007).
7. Jernberg T, Payne CD, Winters KJ et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27, 1166-1173 (2006).
8. Wallentin L, Varenhorst C, James S et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. 29(1), 21-30 (2008).
9. Wiviott SD, Trenk D, Frelinger AL III et al. Prasugrel compared with high loading and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: the PRINCIPLE-TIMI 44 trial. Circulation 116, 2923-2932 (2007).
10. Jakubowski J, Winters KJ, Naganuma H et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies arid the mechanistic basis for its distinct antiplatelet profile. Cardiovasc. Drug Rev. Winter 25(4), 357-374 (2007).
11. Wiviott SD, Antman EM, Winters KJ et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111, 3366-3373 (2005).
12. Wiviott SD, Antman EM, Gibson CM et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic. Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am. Heart J. 152, 627-635 (2006).
13. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
14. Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284, 835-842 (2000).
15. Jakubowski JA, Payne CD, Weerakkody GJ et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J. Cardiovasc. Pharmocol. 49(3), 167-173 (2007).
16. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost. 31(2), 184-194 (2005).
17. Jakubowski JA, Payne CD, Brandt JT et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J. Cardiovasc. Pharmacol. 47, 377-384 (2006).
18. Wiviott SD, Braunwald E, Murphy SA et al. A perspective on the efficacy and safety of intensive antipiatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. AJC 101, 1367-1370 (2008).
19. Cutlip DE, Windecker S, Mehran S et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115, 2344-2351 (2007).
20. Alexander KP, Chen AY, Roe MT et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294, 3108-3116 (2005).
21. Wiviott SD, Brauhwald E, McCabe CH et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371, 1353-1363 (2008).
22. Antman EM, Wiviott SD, Murphy SA et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 Analysis. JACC 51, 2028-2033 (2008).